Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Arch Virol

Retrieve available abstracts of 37 articles:
HTML format

Single Articles

    April 2024
  1. DAS S, Behera P, Shewale DJ, Bodele J, et al
    Development of an effective single-chain variable fragment recognizing a novel epitope in the hepatitis C virus E2 protein that restricts virus entry into hepatocytes.
    Arch Virol. 2024;169:112.
    PubMed     Abstract available

  2. SEDOHARA A, Takahashi K, Arai K, Arizono K, et al
    Characterization of mutations in hepatitis B virus DNA isolated from Japanese HBsAg-positive blood donors in 2021 and 2022.
    Arch Virol. 2024;169:103.
    PubMed     Abstract available

  3. WANG S, Xie Y, Liu F, Wang J, et al
    miR-3188 inhibits hepatitis B virus transcription by targeting Bcl-2.
    Arch Virol. 2024;169:88.
    PubMed     Abstract available

    February 2024
  4. SAID EM, Abdulaziz BA, Kassas ME, El Attar IH, et al
    Retraction Note: High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir the
    Arch Virol. 2024;169:45.

    January 2024
  5. MA X, Li Y, Zhu H, Lu K, et al
    ENPP1 inhibits the transcription activity of the hepatitis B virus pregenomic promoter by upregulating the acetylation of LMNB1.
    Arch Virol. 2024;169:36.
    PubMed     Abstract available

  6. GUPTA S, Parveen S
    Potential role of microRNAs in personalized medicine against hepatitis: a futuristic approach.
    Arch Virol. 2024;169:33.
    PubMed     Abstract available

    October 2023
  7. GAO H, Fan H, Xie H
    miR-HCC2 suppresses hepatitis B virus replication by inhibiting the activity of the enhancer I/X promoter.
    Arch Virol. 2023;168:282.
    PubMed     Abstract available

    June 2023
  8. BHISE N, Agarwal M, Thakur N, Akshay PS, et al
    Correction to: Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus.
    Arch Virol. 2023;168:193.

  9. UPADHYAY R, Tiwari KN
    The antiviral potential of Phyllanthus species: a systematic review.
    Arch Virol. 2023;168:177.
    PubMed     Abstract available

    May 2023
    Vertical transmission of hepatitis B virus from father to child: what can be concluded about this possibility?
    Arch Virol. 2023;168:168.
    PubMed     Abstract available

    April 2023
  11. BHISE N, Agarwal M, Thakur N, Akshay PS, et al
    Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus.
    Arch Virol. 2023;168:147.
    PubMed     Abstract available

    March 2023
  12. ZOU C, Tan H, Zeng J, Liu M, et al
    Hepatitis C virus nonstructural protein 4B induces lipogenesis via the Hippo pathway.
    Arch Virol. 2023;168:113.
    PubMed     Abstract available

    February 2023
  13. ZHANG D, Wang Y, He Y, Ji L, et al
    Identification of avihepadnaviruses and circoviruses in an unexplained death event in farmed ducks.
    Arch Virol. 2023;168:85.
    PubMed     Abstract available

    October 2022
  14. HUAREZ B, Hernandez-Vasquez A, Azanedo D, Vargas-Fernandez R, et al
    Prevalence of hepatitis C virus infection in patients with end-stage renal disease in Latin America and the Caribbean: a systematic review and meta-analysis.
    Arch Virol. 2022 Oct 5. pii: 10.1007/s00705-022-05604.
    PubMed     Abstract available

    September 2022
  15. ABD-ELSALAM S, Sharaf-Eldin M, Soliman S, Elfert A, et al
    Retraction Note to: Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.
    Arch Virol. 2022 Sep 20. pii: 10.1007/s00705-022-05600.

  16. CANCELA F, Noceti O, Arbiza J, Mirazo S, et al
    Structural aspects of hepatitis E virus.
    Arch Virol. 2022 Sep 13. pii: 10.1007/s00705-022-05575.
    PubMed     Abstract available

    May 2022
  17. BOGLIONE L, De Benedetto I, Dodaro V, Chiecchio M, et al
    Role of plasmatic and urinary concentration of tenofovir disoproxil fumarate in a cohort of patients affected by chronic hepatitis B.
    Arch Virol. 2022 May 22. pii: 10.1007/s00705-022-05466.
    PubMed     Abstract available

    March 2022
  18. QU C, Li Y, Li Y, Pan Y, et al
    Full-length MAVS, a mitochondrial antiviral-signaling protein, inhibits hepatitis E virus replication, requiring JAK-STAT signaling.
    Arch Virol. 2022 Mar 24. pii: 10.1007/s00705-022-05415.
    PubMed     Abstract available

    February 2022
  19. SALARI N, Darvishi N, Hemmati M, Shohaimi S, et al
    Global prevalence of hepatitis C in prisoners: a comprehensive systematic review and meta-analysis.
    Arch Virol. 2022 Feb 14. pii: 10.1007/s00705-022-05382.
    PubMed     Abstract available

    January 2022
  20. MESHRAM RJ, Kathwate GH, Gacche RN
    Progress, evolving therapeutic/diagnostic approaches, and challenges in the management of hepatitis C virus infections.
    Arch Virol. 2022 Jan 28. pii: 10.1007/s00705-022-05375.
    PubMed     Abstract available

  21. WOLF JM, Mazeto TK, Pereira VRZB, Simon D, et al
    Recent molecular evolution of hepatitis B virus genotype F in Latin America.
    Arch Virol. 2022 Jan 25. pii: 10.1007/s00705-022-05376.
    PubMed     Abstract available

  22. XU R, Wang H, Huang J, Wang M, et al
    Complete genome sequencing and evolutionary analysis of hepatitis C virus subtype 6a, including strains from Guangdong Province, China.
    Arch Virol. 2022 Jan 20. pii: 10.1007/s00705-021-05358.
    PubMed     Abstract available

    November 2021
  23. SILVA LA, Camargo BR, Araujo AC, Batista TL, et al
    Easily purified baculovirus/insect-system-expressed recombinant hepatitis B virus surface antigen fused to the N- or C-terminus of polyhedrin.
    Arch Virol. 2021 Nov 28. pii: 10.1007/s00705-021-05305.
    PubMed     Abstract available

  24. OKSUZ Z, Ucbilek E, Serin MS, Yaras S, et al
    Possible relationship between IL28B rs12979860 and TLR2 -196 to -174 del/ins polymorphisms and the liver fibrosis stage in hepatitis C patients.
    Arch Virol. 2021 Nov 24. pii: 10.1007/s00705-021-05302.
    PubMed     Abstract available

  25. LIU J, Wang Z, Tang J, Tang R, et al
    Correction to: Hepatitis C virus core protein activates Wnt/beta-catenin signaling through multiple regulation of upstream molecules in the SMMC-7721 cell line.
    Arch Virol. 2021 Nov 4. pii: 10.1007/s00705-021-05275.

  26. CHEN Y, Cai S, Zhang Y, Lai Z, et al
    First identification and genomic characterization of equine hepacivirus subtype 2 in China.
    Arch Virol. 2021;166:3221-3224.
    PubMed     Abstract available

    September 2021
  27. SHEN H, Liu S, Ding M, Gu H, et al
    A quadruple recombination event discovered in hepatitis E virus.
    Arch Virol. 2021 Sep 24. pii: 10.1007/s00705-021-05251.
    PubMed     Abstract available

  28. CHEN Z, Shi SH, Huang Y, Huang CQ, et al
    Differential metabolism-associated gene expression of duck pancreatic cells in response to two strains of duck hepatitis A virus type 1.
    Arch Virol. 2021 Sep 5. pii: 10.1007/s00705-021-05199.
    PubMed     Abstract available

  29. OLAGBENRO M, Anderson M, Gaseitsiwe S, Powell EA, et al
    In silico analysis of mutations associated with occult hepatitis B virus (HBV) infection in South Africa.
    Arch Virol. 2021 Sep 1. pii: 10.1007/s00705-021-05196.
    PubMed     Abstract available

    August 2021
  30. RAO JR, Rafique S, Ali A, Rehman G, et al
    Next-generation sequencing studies on the E1-HVR1 region of hepatitis C virus (HCV) from non-high-risk HCV patients living in Punjab and Khyber Pakhtunkhwa, Pakistan.
    Arch Virol. 2021 Aug 27. pii: 10.1007/s00705-021-05203.
    PubMed     Abstract available

    July 2021
  31. NASIMZADEH S, Azaran A, Jalilian S, Makvandi M, et al
    Prevalence of occult hepatitis C virus infection in beta-thalassemia major patients in Ahvaz, Iran.
    Arch Virol. 2021 Jul 18. pii: 10.1007/s00705-021-05126.
    PubMed     Abstract available

  32. MIRI HH, Fazeli P, Ali-Hassanzadeh M, Bemani P, et al
    Correlation between IL-28 polymorphism and spontaneous clearance in HCV patients: systematic review and meta-analysis.
    Arch Virol. 2021 Jul 3. pii: 10.1007/s00705-021-05141.
    PubMed     Abstract available

    June 2021
  33. PORTILHO MM, Bezerra CS, Mendonca ACDF, Marques VA, et al
    Applicability of oral fluid samples for tracking hepatitis B virus mutations, genotyping, and phylogenetic analysis.
    Arch Virol. 2021 Jun 19. pii: 10.1007/s00705-021-05122.
    PubMed     Abstract available

    May 2021
  34. LI Y, Miao Z, Li P, Zhang R, et al
    Ivermectin effectively inhibits hepatitis E virus replication, requiring the host nuclear transport protein importin alpha1.
    Arch Virol. 2021 May 14. pii: 10.1007/s00705-021-05096.
    PubMed     Abstract available

  35. DE PINA-ARAUJO IIM, Horta MA, do Amaral Mello FC, Soares CC, et al
    Human pegivirus 1 in Cabo Verde: prevalence and genotypic distribution among HIV-infected individuals.
    Arch Virol. 2021;166:1345-1353.
    PubMed     Abstract available

    April 2021
  36. LI MH, Lu Y, Sun FF, Chen QQ, et al
    Transforming growth factor beta as a possible independent factor in chronic hepatitis B.
    Arch Virol. 2021 Apr 19. pii: 10.1007/s00705-021-05062.
    PubMed     Abstract available

  37. ALI NA, Hamdy NM, Gibriel AA, El Mesallamy HO, et al
    Investigation of the relationship between CTLA4 and the tumor suppressor RASSF1A and the possible mediating role of STAT4 in a cohort of Egyptian patients infected with hepatitis C virus with and without hepatocellular carcinoma.
    Arch Virol. 2021 Apr 1. pii: 10.1007/s00705-021-04981.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.